Incyte, Merck shares slide after melanoma therapy fails study


Pedestrians walk across the street from a Merck & Co. facility in Summit, New Jersey
Incyte said on Friday an independent committee concluded that its drug for a type of skin cancer in combination with Merck's Keytruda failed to meet the main goal in a late-stage study.
Incyte shares fell 20 percent in premarket trading Friday, while Merck shares were down about 2 percent.
The two companies would stop the study as it did not meet the primary goal of improving progression-free survival compared to patients on Keytruda monotherapy.
Merck's Keytruda is approved for the treating several forms of cancer, including lung cancer and advanced melanoma. The companies said the study's second main goal of overall survival was also not expected to reach a statistical significance.
The study was evaluating a combination of Incyte's inhibitor Epacadostat and Merck's Keytruda for the treatment of metastatic melanoma.
Incyte said on Friday an independent committee concluded that its drug for a type of skin cancer in combination with Merck's Keytruda failed to meet the main goal in a late-stage study.

Comments

Popular posts from this blog

Kid Rock, Brantley Gilbert to perform at 'Redneck Extravaganza' in Syracuse

Nancy Williams: Easter confusion over bunnies, Bible and baskets

WWE WrestleMania 34 Results: Why Roman Reigns Should Have Defeated Brock Lesnar